Mycophenolate Mofetil (MMF) and Diarrhea

Mechanism and Presentation

• MMF is an immunosuppressive agent that acts by interfering with T-cell proliferation by reversibly blocking the de novo synthesis of guanine nucleotides, affecting both B and T lymphocytes 1
• Diarrhea typically presents as mild to severe watery stools, may be accompanied by abdominal pain, nausea, and vomiting, and can occur at any time during treatment but often appears early and may diminish with continued use 1

Severity and Clinical Implications

• High MMF blood levels may be associated with increased risk of diarrhea 2

Monitoring and Management

• For patients developing diarrhea while on MMF, monitor complete blood count (CBC) and renal/hepatic profiles, and check MMF blood levels if GI intolerance develops - high levels suggest MMF may be causing the diarrhea 2
• Rule out infectious causes with stool analysis for enteropathogens and Clostridium difficile toxin 3
• Management options include for mild diarrhea: anti-diarrheal medications, fluid and electrolyte supplementation while continuing MMF 3
• For persistent or severe diarrhea, dose reduction of MMF 1 or switching to enteric-coated mycophenolic acid (MPA) formulation, which may reduce GI side effects 4

Alternatives for Patients with Severe MMF-Induced Diarrhea

• Alternative immunosuppressants may be considered based on the specific condition being treated, such as Azathioprine 4, Cyclophosphamide 4, Calcineurin inhibitors (cyclosporine, tacrolimus) 5, or Leflunomide 1